View
57
Download
0
Category
Tags:
Preview:
DESCRIPTION
Bio Start-up Proposal
Citation preview
SoilLifeSTART-UP PROPOSAL
Overview Vision Mission Key Product Business Plan (5 years term Goals) Intellectual Property and Patent Drug Development Plan Financial Plan Marketing Plant (Unique selling Points) Team and Company Structure
“
”
To discover and develop new drugs from soil that could be able to treat infections especially caused by multi-resistant pathogens .
Vision
“
”
To bioprospect soil in biodiversity hot spots for the purpose of finding a drug against resistant bacteria as MRSA, Streptoccocus and multiresistant Acinetobacter baumannii.
Mission
Key Product
Our Key Product ”Anneclymycin” is natural product that showed strong antibiotic action against multi resistant Acinetobacter baumannii, a gram negative bacteria which is responsible for difficult to treat wound infection in hospitals
The natural product was originally extracted from professor Nageli’s (Brazil Samples 1991) collected from Brazilian Atlantic Forest and East Island.
Business Plan
Five-years goals :
1. Launch our first product Anneclmycin to the market2. Start clinical trails for another 5 promising antibiotics originiated from soil bioprospecting in Brazil3. Acquisition of 20% of multidrug resistant Acinetobacter baumannii treament market share.
Intellectual Property and License Start Patent application Based on Convention of Biological diversity treaty 1992
and its supplementary agreement Nagoya protocol 2010,
we are planning to reach an agreement with BioAmazonia semi-governmental organization was set up by Brazilian government in order to manage the country's natural genetic resources.
Agreement will allow SoilLife to practice bioprospecting activities in Brazilian Atlantic Forest and Easter Island in compensation to 5 million dollars and 5% sharing of each discovered drug gets to a commercialized product (4% to Bioamazonia and 1% to indigenous people)
Drug Development PlanPromising Data
Investigational drug application
In vivo profiling
Safety studies
Proof of concept trial
New Drug Application
Market Penetration
Financial PlanYear4 Year3 Year2 Year 1
Proof of concept trial
Safety StudiesGMP
Production
In Vivo Profiling and
Production Up scaling
In Vitro profiling and
product optimization
Product development
stage
5 million dollars
Compensation for
Bioamazonia
6 Million Dollars
5 Million dollars
3 Million Dollars
1 Million dollars
External Development
Cost
5 Million Dollars
4.5 Million Dollars
3 Million Dollars
1.5 Million Dollars
Employee cost including
lab Cost
11 Million Dollars
9.5 Million dollars
6 Million Dollars
7.5 Million Dollars
Total
Financial PlanAnticipated
Market ShareCurrent
Market ShareTreatment
Course Cost
25% 0% 800 $ Anneclymycin
30% 40% 1000$ Sulbactam
30% 40% 900$ Carbapenem
15% 20% 2000$ Combination therapy
Financial Plan
At First Four years, Venture Capitalists will invest 34 million dollars before our first product Anneclymycin go to the market.
In Case of failure of investment, merging or acquisition by out-liscencing to another pharmaceutical company.
Marketing Plan
Unique Selling Points
1. Price 2. Single therapy and better patient adherence
The Team CEO
Ann Lee (PhD in molecular biology, PhD thesis about the genome comparison of Acinetobacter baumannii resistant strains.
Vice President Prof. Weiss from ETH Zurich (Supervisor of Ann’s Project )
Vice president Prof. Nageli ( 20 years expereince in natural products and the original author of Brazil Collection)
R&D Manager Dr. Wong(Former Screening department manager at Ninox Pharmaceuticals Basel, Collabotaor of Ann’s Project)
The Team and Company Structure
[Ann Lee ] President,
CEO
[Prof. Weiss ] Vice
President
[TBH] Manager
[TBH] Manager
[Prof. Nageli] Vice
President
[Dr. Wong] R&D
Manager
[TBH] Manager
Recommended